Homebiotech

biotech

MONDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

MONDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 3, 2023

ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies

ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies

January 3, 2023

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action – EIGR

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action – EIGR

January 2, 2023

7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 2, 2023

BLRX NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX

BLRX NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX

January 1, 2023

EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options

EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options

January 1, 2023

ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action – EIGR

ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action – EIGR

December 31, 2022

BLRX SHAREHOLDER ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX

BLRX SHAREHOLDER ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX

December 30, 2022

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action – EIGR

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action – EIGR

December 30, 2022

CLASS ACTION UPDATE for SEDG, EIGR and CURV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

CLASS ACTION UPDATE for SEDG, EIGR and CURV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

December 30, 2022

« 1 … 3 4 5 6 7 … 558 »